MedTrace Logo

Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

NCT01006161 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-10-14

No results posted yet for this study

Summary

Given the strong inhibition of SCH 527123 on neutrophil migration to sites of inflammation, there is a theoretical reason for its use in patients with severe asthma where neutrophils are thought to play a significant role in the pathophysiology of the disease.

Conditions

Interventions

DRUG

SCH 527123

Low dose

DRUG

SCH 527123

Medium dose

DRUG

SCH 527123

High dose

DRUG

SCH 527123

Placebo to match SCH 527123

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-08-31
Completion
2012-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01006161 on ClinicalTrials.gov